title: Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.
abstract: Rilpivirine is a nonnucleoside reverse transcriptase inhibitor used to treat HIV-1. In the present study, the pathways responsible for the biotransformation of rilpivirine were defined. Using human liver microsomes, the formation of two mono- and two dioxygenated metabolites were detected via ultra high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Mass spectral analysis of the products suggested that these metabolites resulted from oxygenation of the 2,6-dimethylphenyl ring and methyl groups of rilpivirine. Chemical inhibition studies and cDNA-expressed cytochrome P450 (CYP) assays indicated that oxygenations were catalyzed primarily by CYP3A4 and CYP3A5. Glucuronide conjugates of rilpivirine and a monomethylhydroxylated metabolite of rilpivirine were also detected and were found to be formed by UDP-glucuronosyltransferases (UGTs) UGT1A4 and UGT1A1, respectively. All metabolites that were identified in vitro were detectable in vivo. Further, targeted UHPLC-MS/MS-based in vivo metabolomics screening revealed that rilpivirine treatment versus efavirenz treatment may result in differential levels of endogenous metabolites, including tyrosine, homocysteine, and adenosine. Rilpivirine biotransformation was also assessed across species using liver microsomes isolated from a range of mammals, and the metabolite profile identified using human liver microsomes was largely conserved for both oxidative and glucuronide metabolite formation. These studies provide novel insight into the metabolism of rilpivirine and the potential differential effects of rilpivirine- and efavirenz-containing antiretroviral regimens on the endogenous metabolome.
authors.affiliation: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
authors.forename: Julie M
authors.initials: JM
authors.lastname: Lade
authors.forename: Lindsay B
authors.initials: LB
authors.lastname: Avery
authors.forename: Namandjé N
authors.initials: NN
authors.lastname: Bumpus
mesh_terms: D000818:Animals; D002853:Chromatography, Liquid; D006224:Cricetinae; D004285:Dogs; D006168:Guinea Pigs; D006801:Humans; D051379:Mice; D008862:Microsomes, Liver / Q000378:metabolism; D009570:Nitriles / Q000378:metabolism*; D011743:Pyrimidines / Q000378:metabolism*; D011817:Rabbits; D051381:Rats; D000068696:Rilpivirine; D053719:Tandem Mass Spectrometry
chemical_list: D009570:Nitriles; D011743:Pyrimidines; D000068696:Rilpivirine
references.citation: Biofactors. 2010 Jan-Feb;36(1):19-24
references.pmid: 20091801
references.citation: Int J Biochem Mol Biol. 2011;2(1):8-23
references.pmid: 21494411
references.citation: Int J Antimicrob Agents. 2013 May;41(5):484-7
references.pmid: 23428312
references.citation: Eur J Pharm Biopharm. 2009 Aug;72(3):502-8
references.pmid: 19328850
references.citation: J Med Chem. 2005 Mar 24;48(6):1901-9
references.pmid: 15771434
references.citation: J Pharmacol Exp Ther. 2012 Dec;343(3):696-703
references.pmid: 22984227
references.citation: Mol Endocrinol. 2002 May;16(5):977-86
references.pmid: 11981033
references.citation: Toxicol Appl Pharmacol. 2011 Dec 1;257(2):227-34
references.pmid: 21958719
references.citation: Lancet. 2011 Jul 16;378(9787):229-37
references.pmid: 21763935
references.citation: Antivir Ther. 2012;17(6):1021-7
references.pmid: 22892398
references.citation: Curr Opin HIV AIDS. 2012 Nov;7(6):600-6
references.pmid: 23032733
references.citation: Biochem Biophys Res Commun. 2010 May 21;396(1):90-4
references.pmid: 20494117
references.citation: Nat Rev Drug Discov. 2002 Apr;1(4):259-66
references.pmid: 12120277
references.citation: Drug Metab Dispos. 2004 Mar;32(3):340-7
references.pmid: 14977869
references.citation: Drug Metab Dispos. 2007 Nov;35(11):2053-9
references.pmid: 17682072
references.citation: Curr Opin Infect Dis. 2012 Oct;25(5):564-9
references.pmid: 22744318
references.citation: Drug Metab Dispos. 2012 Apr;40(4):803-14
references.pmid: 22269145
references.citation: Biochem Pharmacol. 2013 Jun 1;85(11):1700-11
references.pmid: 23583259
references.citation: Drug Metab Dispos. 2007 Dec;35(12):2159-65
references.pmid: 17823234
references.citation: Lancet. 2011 Jul 16;378(9787):238-46
references.pmid: 21763936
references.citation: Biochem J. 1995 Oct 15;311 ( Pt 2):353-66
references.pmid: 7487868
references.citation: Drug Metab Dispos. 2009 Jan;37(1):32-40
references.pmid: 18838504
references.citation: Drug Metab Dispos. 2002 Mar;30(3):235-9
references.pmid: 11854139
references.citation: Annu Rev Pharmacol Toxicol. 2000;40:581-616
references.pmid: 10836148
references.citation: Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6
references.pmid: 15561844
references.citation: J Pharmacol Exp Ther. 2003 Jul;306(1):287-300
references.pmid: 12676886
references.citation: HIV AIDS (Auckl). 2013;5:41-9
references.pmid: 23413112